Establishment of age-specific reference intervals for AMH in Indian women and enhancing its use as a diagnostic marker in PCOS

Sohini Sengupta; Sneha Rawat; Sonu Upadhay; Krishnagopal Chaudhary; Bipendra Singh; M. Halim; Paritosh Gupta

doi:10.18203/2320-1770.ijrcog20232715

Authors

Sohini Sengupta Medical Laboratory Director, Redcliffe Labs, India
Sneha Rawat Department of Clinical Biochemistry and Special Assays, National Reference Laboratory, Redcliffe Labs, India
Sonu Upadhay Department of Clinical Biochemistry and Special Assays, National Reference Laboratory, Redcliffe Labs, India
Krishnagopal Chaudhary Department of Clinical Biochemistry and Special Assays, National Reference Laboratory, Redcliffe Labs, India
Bipendra Singh Department of Clinical Biochemistry and Special Assays, National Reference Laboratory, Redcliffe Labs, India
M. Halim Department of Clinical Biochemistry and Special Assays, National Reference Laboratory, Redcliffe Labs, India
Paritosh Gupta Department of Clinical Biochemistry and Special Assays, National Reference Laboratory, Redcliffe Labs, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20232715

Keywords:

Age-specific reference interval, Cut off value, Specificity and sensitivity, AMH, Diagnostic performance, PCOS

Abstract

Background: Anti Mullerian hormone (AMH) level is a reliable marker of ovarian reserve. It is known to be influenced by factors like age, ethnicity, and ovarian pathology. Establishment of age-specific reference intervals for AMH, characteristic of different nationalities, is therefore of utmost importance. Serum AMH is known to be elevated in women with polycystic ovarian syndrome (PCOS). It is desirable to determine a population-specific cut-off of AMH, for it to be used as a diagnostic marker for PCOS.

Methods: Serum AMH, luteinizing hormone (LH), follicle-stimulating hormone (FSH), Estradiol, Progesterone and Testosterone assays were analyzed in 1978 Indian women, in the age range of 12–50 years. Age-specific reference intervals for AMH were derived for the study population. The cohort of study subjects were then divided into two groups, based on AMH values and clinical history: Control group, and patients with PCOS. The cut-off value of AMH in the study population, corresponding to the diagnosis of PCOS, was also established.

Results: Upper 95th percentile limits of reference intervals for the 18-25 26–30, 31–35, and 36–40, 41-45 and >45 age groups were 9.69, 7.60, 6.50, 6.1, 4.80 and 4.5 ng/ml respectively. In the PCOS group the 5th percentile value was 7.80 ng/ml and the upper 95th percentile was 21.81 ng/ml. The median percentile in PCOS group was 10.40 ng/ml. ROC analysis was done to obtain optimal cutoff values for each age group with better discriminative power than the reference limits. The best cut-off point of AMH value for PCOS in our study population was 7.51ng/ml. The sensitivity and specificity were 99.4% and 95.5%, respectively. The calculated area under the Receiver operating characteristic (ROC) curve was 0.988 (95% CI: 0.984-0.991, P <0.001). AMH, LH, and LH/FSH ratio was significantly higher in the PCOS group than in the control group (p < 0.001 for all comparisons). LH/FSH ratio was more than 2 in the PCOS group compared to controls. Serum Testosterone was significantly higher in PCOS.

Conclusions: The study aids to establish a biological reference interval for AMH, specific for different age groups in Indian women. 7.51ng/ml has been derived as a diagnostic cut-off of AMH for PCOS in our study population. The establishment of age-specific reference intervals, and syndrome-specific cut-offs in the Indian population will help overcome the influence of variables and broaden the use of AMH in women’s health.

Metrics

Metrics Loading ...

References

Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020;105(11):3361-73.

Rosewell KL, Curryl TER. Female Reproduction. Encyclopedia of Reproduction. Elsevier; 2018.

Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.

Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J Environ Res Public Health. 2018;15(11):2589.

Azziz R, Adashi EY. Stein and Leventhal: 80 years on. Am J Obstet Gynecol. 2016;214(2):247.e1-247.e11.

Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008;30(8):671-9.

Bharali MD, Rajendran R, Goswami J, Singal K, Rajendran V. Prevalence of Polycystic Ovarian Syndrome in India: A Systematic Review and Meta-Analysis. Cureus. 2022;14(12):e32351.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.

Leon RLI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. Treasure Island, FL: StatPearls Publishing; 2023.

Karakas SE. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta. 2017;471:248-53.

Butt MS, Saleem J, Aiman S, Zakar R, Sadique I, Fischer F. Serum anti-Müllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. BMC Womens Health. 2022;22(1):199.

Kotlyar AM, Seifer DB. Ethnicity/Race and Age-Specific Variations of Serum AMH in Women-A Review. Front Endocrinol (Lausanne). 2021;11:593216.

Armstrong A, Plowden TC. Ethnicity and assisted reproductive technologies. Clin Pract (Lond). 2012;9(6):651-8.

Nelson SM, Aijun S, Ling Q, Tengda X, Wei X, Yan D, et al. Ethnic discordance in serum anti-Müllerian hormone in healthy women: a population study from China and Europe. Reprod Biomed Online. 2020;40(3):461-7.

Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI. Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women. Fertil Steril. 2014;101(1):199-207.

Gromski PS, Patil RS, Chougule SM, Bhomkar DA, Jirge PR, Nelson SM. Ethnic discordance in serum anti-Müllerian hormone in European and Indian healthy women and Indian infertile women. Reprod Biomed Online. 2022;45(5):979-86.

Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25(1):221-7.

Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91(10):4057-63.

Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkhäuser MH. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril. 2008;89(4):927-33.

Berg MH, Dulmen-den Broeder E, Overbeek A, Twisk JW, Schats R, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod. 2010;25(6):1520-7.

Hagen CP, Sørensen K, Anderson RA, Juul A. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril. 2012;98(5):1326-30.

Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007;87(1):101-6.

Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS. The level of serum anti-Müllerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab. 2012;97(7):2450-5.

Dólleman M, Verschuren WM, Eijkemans MJ, Dollé ME, Jansen EH, Broekmans FJ, et al. Reproductive and lifestyle determinants of anti-Müllerian hormone in a large population-based study. J Clin Endocrinol Metab. 2013;98(5):2106-15.

Kevenaar ME, Themmen AP, Rivadeneira F, Uitterlinden AG, Laven JS, van Schoor NM, et al. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod. 2007;22(9):2382-8.

Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27(2):594-608.

Li HWR, Robertson DM, Burns C, Ledger WL. Challenges in Measuring AMH in the Clinical Setting. Front Endocrinol. 2021;12:691432.

Ahmed N, Batarfi AA, Bajouh OS, Bakhashab S. Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics. 2019;9(4):136.

Saxena U, Ramani M, Singh P. Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome. J Obstet Gynaecol India. 2018;68(2):117-22.

Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014;31(2):213-20.

Sharma P, Chawla R, Ahuja R, Gupta U. Anti-Müllerian Hormone as a Surrogate Marker for Hormonal Dysfunction and Sonographic Pattern in Polycystic Ovarian Syndrome. J South Asian Feder Obst Gynaecol. 2019;11(3):175-80.

Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet. 2014;31(10):1311-6.

Mahajan N, Kaur J. Establishing an Anti-Müllerian Hormone Cutoff for Diagnosis of Polycystic Ovarian Syndrome in Women of Reproductive Age-Bearing Indian Ethnicity Using the Automated Anti-Müllerian Hormone Assay. J Hum Reprod Sci. 2019;12(2):104-13.

Yue CY, Lu LK, Li M, Zhang QL, Ying CM. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One. 2018;13(8):e0203129.

Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28(4):1077-83.

Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59(9):781-90.

Richard SL. Androgen excess disorders. Danforth’s Obstetrics and Gynecology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2003: 663-72.

Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. Med Arch. 2020;74(4):289-93.

Malini NA, Roy George K. Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) - Clinical based case control study. Gen Comp Endocrinol. 2018;260:51-57.

Malini NA, Roy George K. Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) - Clinical based case control study. Gen Comp Endocrinol. 2018;260:51-7.

Ashraf S, Nabi M, Rasool SA. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt J Med Hum Genet. 2019;20:25.